Orphanet Journal of Rare Diseases

Table 3 Adjusted healthcare resource utilization before and after the index date

From: Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States

	Before index date			After index date
Healthcare resource	Attributable effect^υ	95% CI (ROBUST)	P value	Attributable effect^υ	95% CI (ROBUST)	P value
Office visits	+ 0.918	0.207 - 1.628	0.011	+ 1.712	0.897 - 2.528	< 0.001
Outpatient visits	+ 0.209	-0.047 - 0.465	0.110	+ 0.951	0.501 - 1.401	< 0.001
ER visits	- 0.015	-0.072 - 0.042	0.602	+ 0.089	0.013 - 0.165	0.021
Inpatient days	- 0.007	-0.349 - 0.335	0.968	+ 0.017	-0.606 - 0.640	0.957
Other services	+ 0.879	0.406 - 1.351	< 0.001	+ 2.171	1.463 - 2.878	< 0.001
Prescription drugs^ω	+ 0.050	-0.885 - 0.985	0.100	+ 0.449	-8.904 - 2.895	0.482

κ: fully adjusted incidence rate ratio attributable to the presence of AATD; negative binomial model adjusted for age category, gender, race, period of COPD diagnosis census region, oxygen use, Charlson Comorbidity Score, and interaction terms: AATD*CCI, AATD*Oxygen use and AATD*Period of COPD diagnosis
ϒ: number of additional visits/Inpatient days/Prescription drugs on a raw scale attributable to the presence of AATD; negative binomial model
Ω: for a subset of patients who had prescription drug coverage through the same payer

Back to article page

ISSN: 1750-1172

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com